High Alert
Absorption: Well absorbed following oral administration.
Distribution: Crosses the placenta; remainder of distribution unknown.
Protein Binding: >95%.
Half-Life: 0.52 hr.
Contraindicated in:
Use Cautiously in:
EENT: altered visual acuity, ocular disorders, visual disturbances, visual field defects, earache, hearing loss
Resp: asthma, laryngeal edema
CV: CARDIAC FAILURE, MI, STROKE, arrhythmias, chest discomfort, edema, hypertension, hypotension, peripheral edema, phlebitis
GI: GI BLEEDING, abdominal distention, abdominal pain, anorexia, constipation, diarrhea, dry mouth, dyspepsia, hepatosplenomegaly, mucositis, nausea, ulcer, vomiting
GU: renal insufficiency, acute renal failure, dysuria, enlarged prostate, renal tubular necrosis, urinary frequency
Derm: alopecia, cellulitis, dry skin, facial edema, flushing, ↑sweating, pallor, pruritus, rash, skin changes
F and E: acidosis, fluid imbalance
Hemat: disseminated intravascular coagulation, hemorrhage, leukocytosis
MS: bone inflammation, bone pain, flank pain, myalgia
Neuro: paresthesias, SEIZURES, anxiety, confusion, depression, dizziness, fatigue, headache, insomnia, malaise, pseudotumor cerebri, weakness, agitation, cerebral hemorrhage, hallucinations, intracranial hypertension
Misc: fever, infections, pain, hypothermia, retinoic acidacute promyelocytic leukemia syndrome, shivering
Drug-drug:
Drug-Natural Products:
Lab Test Considerations:
Fatalities have occurred with chemotherapeutic agents. Before administering, clarify all ambiguous orders; double check single, daily, and course-of-therapy dose limits; have second practitioner independently double check original order and dose calculations. Tretinoin should be administered only under the supervision of a physician experienced in management of patients with acute leukemia, with monitoring facilities and supportive services available. Do not confuse tretinoin with isotretinoin.